Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. (Amgen): One of the best ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Chemoimmunotherapy offers greater benefits than harms as first-line treatment for older patients with NSCLC, data suggest.

These findings support the need for a phase III randomized controlled trial to definitively determine whether the addition of an antiangiogenic to a second or even a third-generation TKI provides ...

Merck’s investigational KRAS G12C inhibitor, MK-1084 shows antitumor activity in phase 1 trial: Rahway, New Jersey Monday, June 2, 2025, 14:00 Hrs [IST] Merck, known as MSD outs ...

In recognition of its clinical potential, LBL-024 received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) in China (October 2024), and Orphan Drug ...

Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO). This is an ASCO Meeting Abstract ...

The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was ...

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

The primary endpoints of TROPION-Lung02 are dose-limiting toxicities and treatment-emergent adverse events. Secondary endpoints include ORR, DoR, PFS as assessed by investigator, overall survival, ...